A Prospective, Single arm, Multi-centric, Phase IV Study for evaluation of safety and efficacy of Intravenous Levonadifloxacin in Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Wockhardt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

阶段: 4 期
状态: 尚未招募
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Adult subjects of 18 to 65 years of age (both inclusive)
•2.Subjects must be willing to participate in the study and provide a written informed consent
•3.Subjects of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) including diabetic foot infections
•4.Subjects with lesion size area of at-least 75 cm2. Lesion size will be measured by the area of redness, oedema, or induration
•5.Subjects with suspected Gram positive infection clinically and/or documented evidence of Gram-positive infection
•6.Subjects who required intravenous (IV) therapy as per Investigator’s discretion or where oral administration was not feasible

排除标准

•1.a.Clinically diagnosed with impaired blood supply (such that the likelihood of amputation of the infected anatomical site is likely)
•b.ABSSSI expected to require prolonged antimicrobial therapy as per the discretion of the Investigator
•c.Subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene
•d.ABSSSI requiring surgical intervention (except surgical incision and drainage for abscess)
•2.Subjects who have received prior antibiotic therapy within past 24 hours for the treatment of a current episode of ABSSSI. Following are the exception to this criteria:
•a.Subjects who have received a single dose of short acting antibacterial drug within 24 hours of enrolment
•b.Subject with evidence of clinical progression of ABSSSI while on antibacterial drug therapy after at least 48 hours
•c.Subjects who have received an antibacterial drug for surgical prophylaxis and subsequently developed ABSSSI
•3.Subjects with any clinically significant abnormalities in pulmonary, gastrointestinal, endocrine (excluding diabetes mellitus), hepatic or renal systems
•4.Subjects with history of seizures
•5.Subjects with history of hypersensitivity to any of the study drugs or same class of drugs
•6.Sexually active subjects, who are not willing to use contraceptive methods (e.g., hormonal contraceptives, intrauterine devices, barrier method) and pregnant or lactating women
•7.Subjects who received any experimental drug within 30 days prior to enrolment
•8.Subjects with second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, significant ECG abnormalities including QTc = 450 msec
•9.Subjects who, in the judgment of the Investigator, are likely to be noncompliant or uncooperative during the study
•10.Subjects with neoplastic disorder which is either active or has been in remission for less than one year or treatment with antineoplastic drugs within the past 6 months
•11.Subjects with any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination or ECG

研究者

发起方

Wockhardt Ltd

相似试验

尚未招募

4 期

Study of Levonadifloxacin tablet in patients of Bacterial Skin and Skin Structure Infections (ABSSSI)

CTRI/2022/04/042295Wockhardt Ltd

尚未招募

4 期

Safety and Efficacy of Dienogest Tablets in Management of Pelvic Pain Associated with Endometriosis (abnormal tissue growth lying outside uterus)

CTRI/2022/04/041959Sun Pharma Laboratories Limited

已完成

4 期

Safety and Efficacy of Amantadine Tablets for the Treatment of Parkinsons Disease (A disorder of the central nervous system that affects movement, often including tremors) and Drug-induced Extrapyramidal Reactions (involuntary or uncontrollable movements, tremors, muscle contractions) in Patients

CTRI/2023/04/051973Sun Pharma Laboratories Limited (SPLL)163

尚未招募

4 期

Safety and efficacy of Brinzolamide and Timolol eye drops to decrease intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom single drug therapy provides insufficient for intraocular pressure reductio

CTRI/2023/05/052720Sun Pharma Laboratories Limited (SPLL)

已完成

4 期

Safety and Efficacy of Cariprazine Capsules in Adult Patients with Schizophrenia (a disorder that affects a persons ability to think, feel and behave clearly) and Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder (mood swings that include emotional highs and lows)

CTRI/2023/05/052793Sun Pharmaceutical Industries Limited172